Suzetrigine

Brand names: Journavx · Active ingredient: Suzetrigine

In short: JOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults.

Forms & strengthsTablets: 50 mg, blue, film-coated, oblong tablets debossed with "VX50" on one side and plain on the other.
LabelVertex Pharmaceuticals Incorporated
Label updatedOct 09, 2026

What is Suzetrigine used for?

JOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults.

Suzetrigine dosage

Swallow JOURNAVX tablets whole and do not chew or crush.

The recommended starting dose of JOURNAVX is 100 mg orally. Take the starting dose on an empty stomach at least 1 hour before or 2 hours after food to avoid delay in onset of action . Clear liquids may be consumed during this time (e.g., water, apple juice, vegetable broth, tea, black coffee).

Starting 12 hours after the initial dose, take 50 mg of JOURNAVX orally every 12 hours. Take these doses with or without food .

Avoid food or drink containing grapefruit during treatment with JOURNAVX .

Use JOURNAVX for the shortest duration, consistent with individual patient treatment goals. Use of JOURNAVX for the treatment of moderate to severe acute pain has not been studied beyond 14 days.

The recommended dosage of JOURNAVX in patients with hepatic impairment is described in Table 1.

Degree of Hepatic Impairment (HI) | Recommended Dosage

Severe HI (Child-Pugh Class C) | Avoid use .

Moderate HI (Child-Pugh Class B) | Dose 1: The recommended starting dose of JOURNAVX is 100 mg taken orally. Take the starting dose on an empty stomach at least 1 hour before or 2 hours after food . Clear liquids may be consumed during this time (e.g., water, apple juice, vegetable broth, tea, black coffee).

Doses 2, 3, and 4: Starting 12 hours after the initial dose, take 50 mg of JOURNAVX orally every 12 hours. Take these doses with or without food .

Dose 5 and Subsequent Doses: Starting 12 hours after Dose 4, take 50 mg of JOURNAVX orally every 24 hours. Take these dose(s) with or without food .

Mild HI (Child-Pugh Class A) | The recommended dosage is the same as in those with normal hepatic function .

JOURNAVX is contraindicated in patients taking strong CYP3A inhibitors. When JOURNAVX is administered to patients taking moderate CYP3A inhibitors reduce the JOURNAVX dose, as described below:

Dose 1: The recommended starting dose of JOURNAVX is 100 mg orally. Take the starting dose on an empty stomach at least 1 hour before or 2 hours after food . Clear liquids may be consumed during this time (e.g., water, apple juice, vegetable broth, tea, black coffee).

Doses 2, 3, and 4: Starting 12 hours after the initial dose, take 50 mg of JOURNAVX orally every 12 hours. Take these doses with or without food .

Dose 5 and Subsequent Doses: Starting 12 hours after Dose 4, take 50 mg of JOURNAVX orally every 24 hours. Take these dose(s) with or without food .

Avoid food or drink containing grapefruit during treatment with JOURNAVX .

For patients on the standard recommended dosing schedule :

If a dose is missed, take the missed dose as soon as possible and then take the next scheduled dose at the recommended time.

If two or more doses are missed, take 100 mg and then take the next scheduled dose at the recommended time. …

How to take Suzetrigine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Drug Interactions

Ask patients to tell you all the medications they are taking, including any herbal supplements or vitamins .

Food or drink containing grapefruit should be avoided .

When used concomitantly with hormonal contraceptives containing a progestin other than levonorgestrel or norethindrone, advise patients to use an additional nonhormonal contraceptive (such as condoms) or use alternative contraceptives during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX .

Females of Reproductive Potential

Advise females of reproductive potential that JOURNAVX may reversibly impact the likelihood to become pregnant while on treatment. Patients using contraceptives should continue to use contraceptives .

Use in Patients with Hepatic Impairment

Inquire and/or assess whether patients have hepatic impairment.

Administration Instructions

Advise patients to take the starting dose of JOURNAVX on an empty stomach at least 1 hour before or 2 hours after food to avoid delay in onset of action. …

Warnings & precautions

Do not take this medicine if: Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated .

Strong and moderate CYP3A inhibitors increase suzetrigine and M6-SUZ (active metabolite) exposures which may cause JOURNAVX adverse reactions. Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated . Reduce the JOURNAVX dosage with moderate CYP3A inhibitors .

Suzetrigine is an inducer of CYP3A. If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX .

JOURNAVX-treated patients taking concomitant hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives (e.g., a combined oral contraceptive containing ethinyl estradiol as the estrogen and levonorgestrel or norethindrone as the progestin, an intrauterine system) during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX .

Patients with moderate hepatic impairment have higher systemic exposures of suzetrigine and M6-SUZ (active metabolite) than those with normal hepatic function which may increase the risk of JOURNAVX related adverse reactions .

Avoid use of JOURNAVX in patients with severe hepatic impairment (Child-Pugh Class C). The recommended JOURNAVX dosage is lower in patients with moderate hepatic impairment (Child-Pugh Class B) than those with normal hepatic function .

Suzetrigine side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety profile of JOURNAVX is primarily based on data from the pooled, double-blind, placebo- and active-controlled trials in 874 adult patients with moderate to severe acute pain following full abdominoplasty (Trial 1) and bunionectomy (Trial 2) , with supportive safety data from one single arm trial in 256 adult patients with moderate to severe acute pain in a broad range of acute pain conditions (Trial 3).

In Trials 1 and 2, 874 patients received at least one dose of JOURNAVX. The proportion of patients in Trials 1 and 2 who discontinued study drug prematurely due to adverse events was:

0.6% in JOURNAVX-treated patients (postprocedural hematoma [0.2%], hypotension [0.2%], syncope [0.1%]),

0.6% in hydrocodone bitartrate/acetaminophen (HB/APAP)-treated patients (hypotension/orthostatic hypotension [0.2%], migraine [0.1%], intra-abdominal hematoma [0.1%], nausea [0.1%], pyrexia [0.1%]), and

0.2% in placebo-treated patients (hypotension [0.2%], tachycardia [0.2%]).

The safety profile of JOURNAVX was also evaluated by the following subgroup analyses: age (≥ 18 to < 65 years and ≥ 65 years), sex, and race. …

Drug interactions

Table 3 describes drug interactions where concomitant use of another drug affects the use of JOURNAVX.

Strong and Moderate Food or drink containing grapefruit should be avoided during treatment with JOURNAVX. CYP3A Inhibitors

Prevention or Management | Strong CYP3A inhibitors: Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated .

Moderate CYP3A inhibitors: Reduce the JOURNAVX dosage .

Mechanism and Clinical Effect(s) | Suzetrigine and M6-SUZ are CYP3A substrates. Strong and moderate CYP3A inhibitors increase suzetrigine and M6-SUZ (active metabolite of suzetrigine) exposures , which may cause JOURNAVX adverse reactions.

Strong and Moderate CYP3A Inducers

Prevention or Management | Avoid concomitant use of JOURNAVX with strong and moderate CYP3A inducers.

Mechanism and Clinical Effect(s) | Suzetrigine and M6-SUZ are CYP3A substrates. Concomitant use of strong or moderate CYP3A inducers results in reduced exposures of suzetrigine and M6-SUZ, which may result in reduced JOURNAVX efficacy .

CYP3A Substrates

If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. …

About this medicine

The active ingredient in JOURNAVX (suzetrigine) tablets is suzetrigine, a sodium channel blocker, which has the following chemical name:

4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-amido]pyridine-2-carboxamide. Its molecular formula is C21H20F5N3O4.

Suzetrigine's molecular weight is 473.39 g/mol. Suzetrigine has the following structural formula:

Suzetrigine is a white to off-white solid and is practically insoluble in water.

JOURNAVX is available as a blue, film-coated tablet for oral administration containing 50 mg of suzetrigine and the following inactive ingredients: croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, and microcrystalline cellulose. The tablet film coat contains FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.

How it works: Suzetrigine is a selective blocker of the NaV1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (NaV1.1 through 1.9). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f0976da4-1d20-4517-945c-b60ed2f41c12. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine